On Apr. 8, 2020, CSL Behring and SAB Biotherapeutics announced a partnership to combat the coronavirus pandemic with the rapid development of SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation by early summer.

The partnership joined the forces of CSL Behringﾒs leading protein science capabilities with SABﾒs novel immunotherapy platform capable of rapidly developing and producing natural, highly-targeted, high-potency, fully human polyclonal antibodies without the need for blood plasma donations from recovered patients.